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Use of iohexol to quantify hemodialysis delivered and residual
renal function.
Background. Classically, urea (molecular wt 5 60) is used to
determine the urea reduction ratio (URR) or clearance, based on
volume of distribution (Kt/V). These methods are subject to many
errors. The purpose of this study was to determine whether
iohexol (Io; molecular wt 5 821) could be used instead of urea
and provide better information as well as middle molecule
clearance data.
Methods. Ten hemodialysis (HD) patients were evaluated. All
were dialyzed for three hours, and a single bolus of 100 ml of Io
was injected immediately post-HD. For direct dialysis quantifica-
tion (DDQ), the spent dialysate was collected in a drum, and urea
and iodine (I) determined immediately prior to, at the end of, and
30 minutes post-HD. As routinely used, DDQ measures clearance
directly rather than estimates the levels.
Results. Calculated Kt/V urea (1.21 6 0.05) significantly over-
estimated DDQ Kt/V urea (0.78 6 0.04, P , 0.001) whereas
calculated and DDQ Kt/V Io were similar (1.44 6 0.10 vs. 1.36 6
0.05). The URR and iohexol reduction ratio (IoRR) were also
different (0.63 6 0.02 vs. 0.69 6 0.02; P , 0.002) with a urea but
not Io rebound (URR30 min 0.59 6 0.02, P , 0.05). Calculated
urea clearance (Curea), 247 6 21 ml/min, significantly overesti-
mated DDQ Curea (157 6 10 ml/min P , 0.001). Calculated CIo
and DDQ CIo, however, were similar (109 6 8 vs. 104 6 7
ml/min). Total body clearance (TBC) in six anuric subjects was
2.5 6 0.3 ml/min, and in four oliguric subjects was 5.2 6 0.5
ml/min. In 10 additional patients, direct urine measurements
demonstrated a non-renal clearance (NRC) of 2.97 6 0.18
ml/min, which was 4.0 6 0.3% of body wt. Use of this factor
allowed an estimation of residual renal function (RRF) that
accurately reflected measured RRF (1.32 6 0.53 vs. 1.42 6 0.55
ml/min)
Conclusion. A single injection of Io can be used to determine
Kt/V, RR, and RRF without rebound or the inconvenience of
urine collection. It may also represent middle molecule clearance
better than urea kinetics, and may serve as a superior method for
determining HD delivered and dialysis adequacy.
In the past decade end-stage renal disease (ESRD) in the
United States (US) has grown exponentially at the rate of
nearly 9% per year [1]. Approximately 270,000 patients
received treatment in 1995, of which 60% were using
hemodialysis (HD) as renal replacement therapy [1]. De-
spite advances in medical management, survival of ESRD
patients on HD in the US is lower compared to HD-
dependent ESRD patients in other developed countries.
The five year survival rates for ESRD patients initiating
renal replacement therapy in 1982 in Japan, Europe, and
the US were 61%, 59% and 40%, respectively [2]. Several
studies have shown that a major factor in survival is the
dose of dialysis received by ESRD patients [3–6]. If the
amount of dialysis plays a major role in the morbidity and
mortality of ESRD patients, then an accurate way of
quantifying HD is needed. During the past twenty years,
several methods have been developed for this purpose.
Currently, the most widely used method is Kt/V using urea
modeling. It is an expression developed by Gotch and
Sargent in their mechanistic analysis of the National Co-
operative Dialysis Study [7]. Kt/V has been criticized
because of the complex mathematical calculation, problems
with urea rebound, and a tendency to overestimate true
clearances [8–10].
Residual renal function (RRF) in these ESRD patients is
important, not only because the native kidneys filter larger
molecules than dialysis membranes, but also may contrib-
ute a substantial amount to the total clearance [11]. A
24-hour urine collection is needed for RRF determination.
This is difficult in HD patients and may be quite inaccurate
because of a failure to reflect the true glomerular filtration
rate (GFR) [11]. Utilization of isotopic tracers to deter-
mine RRF is much more accurate, but requires a radioac-
tive isotope and is labor intensive. Renal clearance of
iohexol (CIo), a non-radioactive non-ionic radiocontrast
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agent, has been shown to provide an accurate measure of
RRF [12] and is as accurate as inulin and other methods
of measuring renal function [13–18]. In addition, its molec-
ular weight, 821 kD, is comparable to the elusive middle
molecules that may be important in the symptoms and
complications of uremia, the clearances of which are diffi-
cult to determine [17–20].
The purpose of the present study was to (1) determine
whether Io can be used as a method for quantifying HD, (2)
to determine whether a single injection of Io will allow
determination of RRF, and (3) to compare Io and urea
modeling.
METHODS
Patient population
Ten ESRD patients being treated at the University of
Virginia Kidney Center were studied. Their mean age was
67 6 3 years, four male and six female, and all were African
American. The study protocol was approved by the Insti-
tutional Review Board. Informed consent was obtained
after ascertaining that patients were not allergic to dye or
seafood, and had not had a radiocontrast dye examination
within one week of the study. All subjects received their
routine HD via high flux F-80 Fresenius dialyzers. The
dialysis flow rate (DFR) and duration of treatment were
prescribed for 500 ml/min and three hours, respectively,
with maximal blood flow rates (BFR). Attained duration
was 3.20 6 0.04 hours with DFR of 532 6 13 ml/min and
BFR of 322 6 19 ml/min. The hematocrits of the patients
were 33.1 6 1.2 vol %.
Interventions
Patients received an intravenous bolus of 100 ml of
non-ionic Io [Omnipaque 350 containing 350 mg elemental
iodine (I)/ml] following a routine HD treatment. This
quantity of Io was necessary to achieve sufficient dialysate
concentrations for the direct method described below. For
studies using plasma samples alone, patients received 30 ml
Io, which provided I levels sufficient to analyze. At the next
treatment, blood samples were obtained for urea and I
determination at the start, immediately after, and at 30
minutes post-HD. For blood samples obtained at time zero
or end of dialysis, patients were disconnected, blood was
aspirated and returned twice, and the third sample was
taken as end of dialysis. The needle was blocked with saline
and the 30 minute sample was similarly obtained. Urea and
Io measurements were performed concurrently in the same
patients. The experimental protocol in a typical patient is
illustrated in Figure 1.
Reference method
The direct dialysis quantification method (DDQ) was
used as the absolute standard for dialyzer clearance [8, 10].
The total dialysate was collected during the treatment using
a 55 gallon drum and immediately analyzed for urea and
iohexol (Io). DDQ produces accurate measurement of
clearance, but since it involves collection of 100 to 150 liters
of dialysate per treatment, this method cannot be used as a
routine way of monitoring adequacy of HD. However,
DDQ serves as a standard for evaluation of other methods
[19]. No urine was collected from these 10 patients studied
by the DDQ method.
Clinical parameters
The following parameters were determined: Kt/V for
urea and Io; calculated urea clearance (Curea) and CIo; urea
and Io reduction ratio (RR); Curea and CIo by DDQ; RRF;
total body clearance (TBC) of Io; and non-renal clearance
of Io (NRC). Plasma and dialysate I concentration were
measured using the Renalyzer PRX90 (Provalid AB, Lund,
Sweden). The Renalyzer is a self-contained unit into which
samples are placed and consequently bombarded by high
energy photons from 241Americium. Iodine atoms in the
sample become excited from this irradiation and emit
x-radiation (x-ray fluorescence) detected by a sodium io-
dide crystal. The x-ray fluorescence is proportional to the
amount of iodine present. Standards are determined in the
same fashion and time as the unknown. Measuring time
was 300 seconds per sample. The system is linear over the
range from 0.03 to 7.00 mg/dl I, which included concentra-
tions measured in the study [21].
Analytical methods
Kt/V is a measure of the amount of plasma cleared of
solute (K) during a time interval (t) divided by the solute
distribution volume (Vd) [22].
Fig. 1. Illustration of iodine (I) concentrations and sampling times after
intravenous administration of iohexol (Io) at time 0. Sample A was drawn
at the initiation of hemodialysis (HD) 45 hours after Io injection, B at the
end of HD, and C at 30 minutes after termination of HD. Total body
clearance (TBC) of Io by the Jacobsson formula was determined from A,
HD clearance kinetics from points A and B, and the effect of rebound on
clearance from A and C. Residual renal function (RRF) was estimated by
TBC 2 non-renal clearance (NRC; 0.04 3 total body wt or about 3
ml/min).
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Kt/V 5
Clearance 3 time
Vd (Eq. 1)
The second generation Daugirdas formula (logarithmic)
based on ratio (R) of post-dialysis/pre-dialysis concentra-
tion of urea and ultrafiltrate (UF)/post-dialysis weight in kg
(W) was used to calculate Kt/V [23].
Kt/V 5 2ln ~R 2 0.008 * t! 1 ~4 2 3.5 3 R! 3 UF/W
(Eq. 2)
Calculated Curea was determined by combining equation 1
and equation 2.
Clearance 5
F2ln~R 2 0.008 p t! 1 ~4 2 3.5 3 R! 3 UF/Wtime G 3 Vd
(Eq. 3)
The reduction ratio (RR) was calculated using [24]
URR 5 1 2
Post-BUN or Io
Pre-BUN or Io (Eq. 4)
The Renalyzer program for calculation of clearance
based on a single sample taken more than three hours after
injection is described by Jacobsson [25]. This formula in the
Renalyzer software includes two correction factors, one for
non-uniform distribution of tracer “m,” and another for
non-immediate mixing, “r.” In order to correct for non-
uniform tracer distribution and mixing, an approximate
clearance is calculated and corrected for “m” and “r.” The
value for each of these is essentially 1.0 in renal failure [25].
Clearance 5
1
t/V9 1 0.0016 3 ln @Qtot/V 3 C~t!# (Eq. 5)
Where Qtot is the total iodine injected, t is the time
interval after injection, C(t) the iodine concentration
in the plasma sample at time (t), and V9 5 V/m and
m 5 0.991 * 0.0012 * clearance, while r 5 0.495 3 (1 1
=1–0.0049 clearance), or approximately 20.0016 (ml/min)21
[25].
It is necessary to know the Vd of urea or Io to convert
Kt/V to clearance. Vd urea is approximately equivalent to
total body water (TBW). Sex-specific formulae from Hume
and Weyers [26] based on the tritium space was used to
calculate TBW for urea studies. The VdIo was calculated
according to the following formula [21].
VdIo 5 131 3 W 1 4330; ~w . 30 kg! (Eq. 6)
VdIo 5 263 3 W 1 416; ~w , 30 kg! (Eq. 7)
The Vd of Io in our patients was 0.19 liter/kg, similar to
that reported in the literature [27, 28].
Error in estimation of the Vd has minimal impact on
clearance in patients with low clearance and sampling times
beyond 300 to 500 minutes [25]. Curea and CIo by DDQ
were determined using:
Clearance ~DDQ! 5
Fconc of I or ureaPre 1 post-conc
2 3
volume of dialysate
time
G (Eq. 8)
Total body clearance (TBC) of Io. The TBC of Io was
determined from the plasma I concentration obtained
immediately predialysis (point A in Fig. 1), utilizing the
Renalyzer single sample calculation [21, 25].
Residual renal function
In patients with ESRD, a small amount of RRF may
persist for a short while and then is lost. RRF is equal to
TBC minus non-renal elimination or clearance (NRC) of
tracer agent. Since NRC is constant at about 2 to 3 ml/min,
RRF can be estimated by subtracting 2 to 3 ml/min from
TBC or by directly measuring RRF [11, 12, 29]. In the
present studies, these relationships were assessed.
Direct iohexol clearance
To directly determine renal Cl, ten additional patients
received 30 ml Io at the end of dialysis. These patients were
slightly younger than those studied by DDQ (52.9 vs. 67
years, P , 0.05), but race, sex, body wt, and height were not
different. Patients collected urine for 48 hours until the
next dialysis when blood was drawn for I determination.
The total amount of I in the urine was also determined.
Direct Cl was calculated by the formula (from Fig. 1, at
time point 0 and A, data provided by the program in the
Renalyzer), with
I0 5
dose Io
VdIo
(Eq. 9)
CIo 5
Urine 1 3 Volume
I0 1 IA
2 3 time
(Eq. 10)
Non-renal clearance
The non-renal clearance (NRC) was directly determined
in the 10 patients producing urine by calculating the TBC
from point A, Figure 1, and subtracting the measured RRF
from the TBC.
NRC 5 TBC 2 RRF (Eq. 11)
When patients did not produce urine, NRC 5 TBC.
Data analysis
Statistical analyses included correlation coefficient, lin-
ear regression and paired “t” testing with the Statmost data
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analysis system. All values are expressed as mean 1 SEM,
and P , 0.05 was considered significant.
RESULTS
The results of our studies are presented in Tables 1 to 3.
A comparison of the mean values of Kt/V, clearance,
reduction ratio for both urea and Io using post-dialysis
samples, and equilibrated samples (30 min post-HD) mea-
sured by DDQ and calculated are shown in Table 1.
Calculated Kt/V urea was significantly lower than Kt/V Io,
calculated or DDQ, and demonstrated a significant re-
bound in the 30 minute studies. Calculated Kt/V of urea at
0 and 30 minutes significantly overestimated Kt/V of urea
by DDQ by about 40%, while Kt/V Io was similar for
calculated and DDQ, and did not demonstrate any re-
bound. URR was likewise significantly lower than IoRR
and showed a significant 30-minute rebound not observed
with IoRR. The Curea was approximately 40% higher than
CIo for the entire range of values determined. Curea was
also significantly greater at immediate post-dialysis and the
30 minute samples compared to Curea by DDQ. The
difference between Curea at 0 minutes and 30 minutes
tended towards significance for both the calculated (P 5
0.08) and DDQ measurements (P 5 0.06). Conversely, CIo
at 0 and 30 minutes, whether calculated or by DDQ, were
not different. Table 2 presents correlative data for the two
methods. There was an excellent correlation between cal-
culated Kt/V of urea and of Io (Rs 5 0.74, P , 0.01).
Likewise, URR and IoRR exhibited a high correlation
(Rs 5 0.68, P , 0.02) There was a similarly high correlation
between calculated Curea and calculated CIo (Rs 5 0.59,
P , 0.05). There was also an excellent correlation between
calculated Curea and Curea by DDQ. However, calculated
Curea again overestimated Curea by DDQ by about 50%
(Table 1). On the other hand, calculated CIo was highly
correlated with DDQ CIo (Rs 5 0.673, P , 0.02) but with
a much higher accuracy (y 5 0.93x 2 1.13). Calculated CIo
was within 10% of CIo by DDQ (Table 1).
The measured TBC, RRF, and NRC of the additional 10
patients in whom urine I was determined are presented in
Table 3. NRC in these 10 patients was 3.8 6 0.3% of body
wt or 4.0 6 0.3% of body wt corrected to 1.73 m2 as utilized
by the Renalyzer. The uncorrected NRC was 2.78 6 0.19
ml/min (1.9 to 4.0 ml/min) and 2.97 6 0.18 ml/min/1.73 m2
(1.9 to 4.0 ml/min/1.73 m2). Estimated RRF, empirically
determined by subtracting 3.0 ml/min for NRC, was 1.42 6
0.55 ml/min/1.73 m2 compared to directly measured RRF,
Table 1. Mean values of kinetic parameters determined for urea and iohexhol
Urea Iohexol
Calculated DDQ Calculated DDQ
Kt/V, 0 min 1.21 6 0.05a 0.78 6 0.04a,b 1.44 6 0.10c 1.36 6 0.05d
Kt/V, 30 min 1.10 6 0.07 0.76 6 0.04b 1.44 6 0.10c 1.35 6 0.05d
RR, 0 min 0.63 6 0.02a 0.69 6 0.02e
RR, 30 min 0.59 6 0.02 0.69 6 0.02e
Clearance 0 min ml/min 247 6 21 157 6 10b 109 6 8c 104 6 7d
Clearance 30 min ml/min 223 6 17 152 6 9b 110 6 11c 103 6 7d
Abbreviations are: DDQ, direct dialysis quantification; zero min, end of dialysis sample obtained as described in text; RR, reduction ratio; URR, urea
reduction ratio. Iodine levels in mg/ml were predialysis 1.31 6 0.14 (0.67 to 2.20) and post-dialysis 0.37 6 0.03 (0.22 to 0.57); and dialysate was 0.16 6
0.01 (0.08 to 0.21).
a P , 0.05 vs. 30 minute urea parameters
b P , 0.001 vs. calculated urea parameters
c P # 0.005 vs. calculated and DDQ urea
d P , 0.001 vs. calculated and DDQ urea
e P , 0.002 vs. URR
Table 2. Relationship between iohexol and urea kinetic determinations
Comparisons Equation Rs P
Calculated Kt/V y 5 1.36x 2 0.423 0.74 , 0.01
Reduction ratio y 5 1.09x 1 0.0057 0.68 , 0.02
Calculated clearance y 5 0.279x 1 27.3 0.59 , 0.05
Calculated Curea vs. DDQ Curea y 5 1.96x 2 63.1 0.82 , 0.01
Calculated CIo vs. DDQ CIo y 5 0.93x 2 1.13 0.67 , 0.02
Abbreviations are: Curea and CIo, urea and iohexol clearance, respec-
tively. Rs 5 r2; DDQ, direct dialysis quantification;
Table 3. Estimation of residual renal function from iohexol kinetics
and direct measurement
Calculated Measured
TBC 2.45 6 0.29a
5.20 6 0.46b
NRC 2.97 6 0.18c
RRF 1.42 6 0.55d 1.32 6 0.53e
2.20 6 0.47f
Abbreviations are: TBC, total body clearance, ml/min/1.73 m2; NRC,
non-renal clearance, ;3 ml/min/1.73 m2; RRF, residual renal function,
ml/min/1.73 m2.
a TBC determined by CIo in 6 anuric patients studied by DDQ
b TBC determined by CIo in 4 oliguric patients studied by DDQ
c NRC measured directly by urine I in 10 patients with collected urine
(NRC 5 TBC-urine I)
d RRF estimated by TBC 2 NRC for the 10 patients with urine
production
e RRF by direct 48 hour urine CIo in the same 10 patients with urine
production
f RRF estimated by TBC 2 NRC for the 4 oliguric patients studied by
DDQ
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1.32 6 0.53 ml/min/1.73 m2. The TBC and RRF data for
the 10 patients studied by DDQ but without urine collec-
tion are also presented in Table 3. For anuric patients,
TBC 5 NRC, and was similar to the additional patients
from whom urine was collected (2.45 6 0.29 vs. 2.97 6 0.18
ml/min.1.73 m2). Subtraction of the correction factor for
NRC determined for the four oliguric patients without
urine collections yielded an estimate of 2.20 6 0.47 ml/min/
1.73 m2.
All patients tolerated the studies without side effects.
DISCUSSION
Since HD became available, the nephrologist has been
challenged to assess adequacy and quantify the amount of
HD delivered relative to that prescribed. Urea kinetic
modeling is a remarkable conceptual advancement and a
useful tool for understanding the physiology and quantifi-
cation of dialysis, but cannot be a standard for adequacy,
since it is both approximate and unvalidated [9].
To our knowledge, ours is the first study assessing the
accuracy of plasma CIo in quantifying the amount of HD
delivered. Our data show that a single bolus of Io injected
immediately post-HD allows the calculation of TBC and an
estimate of RRF (Table 3), as has been shown by Swan et
al [12], and of CIo, Kt/V, and RR.
Out of the ten patients studied by DDQ, six patients were
not producing urine, and of the remaining four patients,
two were incontinent. No reliable 24 hour urine sample was
collected, but the average TBC by plasma CIo of the four
oliguric patients was 5.2 6 0.46 ml/min. The average TBC
(same as NRC) by CIo of the six patients who were anuric
was 2.45 6 0.29 ml/min, which was similar to the TBC or
NRC of anephric patients in other studies [11, 12, 29]. This
further supports the theory of a small amount of extrarenal
clearance of Io. This small endogenous clearance was
similar to that reported by others and determined in our
ten patients with urine production. This permitted estima-
tion of NRC CIo. Since this was approximately 4% of body
wt or 3 ml/min, this allowed us a relatively accurate
estimate of RRF using a single injection of Io without
collecting urine, by subtracting this “constant” NRC from
TBC determined by Io. Any variability in the actual and
estimated RRF would be very small because of the minimal
NRC of Io observed here and by others [12].
The results of the Io method correlated well with results
using urea modeling. CIo, Kt/V and IoRR correlated highly
with Curea, Kt/Vurea and URR, respectively. However,
calculated Curea overestimated HD delivery by about 50%
compared to DDQ, while CIo was equivalent to DDQ. The
tendency of urea kinetic modeling to overestimate Cl
compared to DDQ has been shown in previous compara-
tive studies of these two methods [10, 19]. Rebound was
observed for URR and Kt/V urea between the time of
dialysis termination and the 30 minutes post-sample (Table
1), but not for Io. This is consistent with a Vd for Io of
extracellular water, as opposed to the TBW of urea.
CIo was lower compared to Curea because of the low
molecular weight of urea (molecular wt 5 60) compared to
Io (molecular wt 5 821), which is a size similar to middle
molecules. The Vd of these molecules is not known, but
evidence suggests they may be distributed in extracellular
water, which is the same Vd as Io [20]. The middle
molecule theory claims that larger molecular weight species
(molecular wt 500 to 5,000) that dialyze slowly may be
responsible for uremic toxicity [17–20]. Numerous attempts
have been made to prove or disprove this hypothesis [30].
Some of these studies support a toxic role for these
molecules while others do not. There have not previously
been convenient markers of middle molecule clearance.
Our studies suggest Io may have utility as a surrogate
marker of middle molecules and enhance studies of these
questions.
The volume of Io used was calculated to provide an
adequate concentration of I in the larger volume of directly
collected dialysate. Post-dialysis I concentration can be
accurately measured with smaller amounts (30 ml of 350
mg/ml) of Io. Io as used here is safe and represents a small
dose used clinically for imaging studies.
Io is considered to be the least nephrotoxic contrast
agent currently available [31]. Io and the other contrast
agents have been given repeatedly to patients in the clinical
setting and in studies serially assessing renal function. No
change in renal function or enzymuria suggesting subclini-
cal renal damage have been observed in other studies [12,
29, 32]. The risk of death has been estimated , 1:100,000
injections with severe reactions in about 0.01 to 0.2% [33].
There were no side effects noted in the patients studied.
In conclusion, the results of our study showed that Io
provides a simple and accurate way of quantifying HD
delivery without rebound with the added advantage of
enabling the clinician to estimate RRF and middle mole-
cule clearance. Large scale, prospective studies in the
context of assessment of HD delivered and adequacy of
dialysis, in parallel with urea kinetics, will be needed to
assess the ability of Io kinetics to accurately reflect ade-
quacy of dialysis and determine if it can more truly reflect
dialysis delivered than current methodologies.
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APPENDIX
Abbreviations used in this article are: DDQ, direct dialysis quantifica-
tion; DFR, dialysis flow rate; ESRD, end-stage renal disease; GFR,
glomerular filtration rate; HD, hemodialysis; HDD, hemodialysis deliv-
ered; Io, iohexol; NRC, non-renal clearance; RR, reduction ratio; RRF,
residual renal function; TBC, total body clearance; TBW, total body
water; UF, ultrafiltrate; URR, urea reduction ratio; US, United States;
Vd, distribution volume.
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